Table 2.
Immunohistochemistry for URG11 and HBxAg in Tumor/Nontumor Pairs from HCC Patients.
| South african patients | Uninfected livers | ||||||||||||||||
| Case number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 1 | 2 | |
| T | URG11 | 1 | 1 | 0 | 2 | 1 | 0 | 2 | 1 | 2 | 0 | 2 | 0 | 2 | 2 | ||
| HBxAg | 0 | 1 | 0 | 2 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | |||
| NT | URG11 | 4 | 3 | 1 | 2 | 4 | 3 | 3 | 2 | 2 | 1 | 3 | 0 | 3 | 4 | 1 | 1 |
| HBxAg | 1 | 2 | 1 | 3 | 3 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | |
| Chinese patients | ||||||||||||||||||||||||
| Case number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | |
| T | URG11 | 1 | 1 | 2 | 0 | 0 | 2 | 0 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 1 |
| HBxAg | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | |
| NT | URG11 | 3 | 2 | 3 | 1 | 3 | 2 | 2 | 3 | 2 | 1 | 3 | 3 | 2 | 3 | 3 | 2 | 2 | 0 | 3 | 2 | 3 | 3 | 4 |
| HBxAg | 3 | 1 | 1 | 2 | 1 | 2 | 1 | 3 | 1 | 0 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 0 | 1 | 2 | 1 | 2 | 2 | |
Staining is estimated as follows: 0 = no signal; 1 = IHC signal in <10% of cells; 2 = IHC signal in 10% to 25% of cells; 3 = IHC signal in 25% to 50% of cells; and 4 = IHC signal in >50% of cells.